Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Targeting CD40 in Waldenstrom's Macroglobulinemia

Targeting CD40 in Waldenstrom's Macroglobulinemia 5th International Workshop on Waldenstroms Macroglobulinemia Lee, M., Advani, R. CIG MEDIA GROUP, LP. 2009: 87–89

Abstract

CD40 is a member of the tumor necrosis factor (TNF) receptor family and is expressed in a majority of B-cell malignancies. In Waldenström's macroglobulinemia (WM), CD40 expression is a common feature of bone marrow infiltrating lymphoplasmacytic cells, and preclinical evidence suggests that CD40 signaling is functionally important for WM growth and survival. Two antibodies targeting CD40 (SGN-40 and HCD 122 [Chir 12.12]) are currently undergoing clinical testing in multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). HCD122 is a novel, fully human, IgG1 antagonistic monoclonal antibody while SGN-40 is a humanized IgG1 partial agonistic antibody. Both agents have demonstrated activity in preclinical models and are potent mediators of antibodydependent cellular cytotoxicity (ADCC). Clinically, phase I data suggest both agents are well tolerated with no immunogenicity and have early evidence of single-agent clinical activity in relapsed and refractory NHL and MM. These observations support the testing of CD40-targeted agents in WM.

View details for DOI 10.3816/CLM.2009.n.023

View details for PubMedID 19362983